XML 19 R10.htm IDEA: XBRL DOCUMENT
v3.22.2.2

REVENUES | 9 Months Ended
--- | ---
Sep. 30, 2022
Revenue from Contract with Customer [Abstract] |
REVENUES | REVENUES Disaggregation of Revenues The following table summarizes our Total revenues:
|  | Three Months Ended September 30, 2022 |  | Three Months Ended September 30, 2021
(in millions) |  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 2,286 |  |  | $ | 278 |  |  | $ | 201 |  |  | $ | 2,766 |  |  | $ | 1,875 |  |  | $ | 254 |  |  | $ | 147 |  |  | $ | 2,276 |
Complera/Eviplera |  | 20 |  |  | 21 |  |  | 3 |  |  | 43 |  |  | 28 |  |  | 31 |  |  | 5 |  |  | 64 |
Descovy |  | 444 |  |  | 28 |  |  | 28 |  |  | 500 |  |  | 355 |  |  | 42 |  |  | 36 |  |  | 433 |
Genvoya |  | 502 |  |  | 71 |  |  | 27 |  |  | 600 |  |  | 576 |  |  | 100 |  |  | 68 |  |  | 744 |
Odefsey |  | 276 |  |  | 86 |  |  | 12 |  |  | 374 |  |  | 275 |  |  | 112 |  |  | 12 |  |  | 399 |
Stribild |  | 22 |  |  | 7 |  |  | 3 |  |  | 32 |  |  | 28 |  |  | 11 |  |  | 3 |  |  | 42 |
Truvada |  | 24 |  |  | 3 |  |  | 2 |  |  | 30 |  |  | 55 |  |  | 5 |  |  | 7 |  |  | 67 |
Revenue share - Symtuza(1) |  | 85 |  |  | 40 |  |  | 4 |  |  | 130 |  |  | 86 |  |  | 41 |  |  | 3 |  |  | 130 |
Other HIV(2) |  | 1 |  |  | 6 |  |  | 5 |  |  | 12 |  |  | 24 |  |  | 6 |  |  | 4 |  |  | 34 |
Total HIV |  | 3,661 |  |  | 541 |  |  | 285 |  |  | 4,487 |  |  | 3,302 |  |  | 602 |  |  | 285 |  |  | 4,189 |
Veklury |  | 336 |  |  | 130 |  |  | 458 |  |  | 925 |  |  | 1,527 |  |  | 109 |  |  | 287 |  |  | 1,923 |
Hepatitis C virus (“HCV”) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ledipasvir/Sofosbuvir(3) |  | 8 |  |  | 5 |  |  | 12 |  |  | 25 |  |  | 14 |  |  | 5 |  |  | 26 |  |  | 45 |
Sofosbuvir/Velpatasvir(4) |  | 241 |  |  | 131 |  |  | 84 |  |  | 455 |  |  | 173 |  |  | 77 |  |  | 82 |  |  | 332 |
Other HCV(5) |  | 34 |  |  | 7 |  |  | 2 |  |  | 44 |  |  | 37 |  |  | 12 |  |  | 3 |  |  | 52 |
Total HCV |  | 283 |  |  | 143 |  |  | 98 |  |  | 524 |  |  | 224 |  |  | 94 |  |  | 111 |  |  | 429 |
Hepatitis B virus (“HBV”) / Hepatitis delta virus (“HDV”)
Vemlidy |  | 129 |  |  | 9 |  |  | 90 |  |  | 228 |  |  | 103 |  |  | 9 |  |  | 96 |  |  | 208 |
Viread |  | 2 |  |  | 5 |  |  | 15 |  |  | 22 |  |  | 1 |  |  | 7 |  |  | 18 |  |  | 26 |
Other HBV/HDV(6) |  | — |  |  | 13 |  |  | — |  |  | 14 |  |  | — |  |  | 13 |  |  | — |  |  | 13 |
Total HBV/HDV |  | 131 |  |  | 28 |  |  | 106 |  |  | 264 |  |  | 104 |  |  | 29 |  |  | 114 |  |  | 247 |
Cell therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 60 |  |  | 20 |  |  | 1 |  |  | 81 |  |  | 35 |  |  | 12 |  |  | — |  |  | 47 |
Yescarta |  | 210 |  |  | 91 |  |  | 16 |  |  | 317 |  |  | 100 |  |  | 66 |  |  | 9 |  |  | 175 |
Total cell therapy |  | 270 |  |  | 111 |  |  | 17 |  |  | 398 |  |  | 135 |  |  | 78 |  |  | 9 |  |  | 222 |
Trodelvy |  | 139 |  |  | 38 |  |  | 3 |  |  | 180 |  |  | 100 |  |  | 1 |  |  | — |  |  | 101 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 9 |  |  | 63 |  |  | 33 |  |  | 105 |  |  | 7 |  |  | 67 |  |  | 69 |  |  | 143 |
Letairis |  | 43 |  |  | — |  |  | — |  |  | 43 |  |  | 46 |  |  | — |  |  | — |  |  | 46 |
Other(7) |  | 28 |  |  | 11 |  |  | 13 |  |  | 52 |  |  | 34 |  |  | 17 |  |  | 5 |  |  | 56 |
Total other |  | 80 |  |  | 75 |  |  | 46 |  |  | 200 |  |  | 87 |  |  | 84 |  |  | 74 |  |  | 245 |
Total product sales |  | 4,900 |  |  | 1,064 |  |  | 1,013 |  |  | 6,978 |  |  | 5,479 |  |  | 997 |  |  | 880 |  |  | 7,356 |
Royalty, contract and other revenues |  | 28 |  |  | 37 |  |  | — |  |  | 64 |  |  | 30 |  |  | 34 |  |  | 1 |  |  | 65 |
Total revenues |  | $ | 4,928 |  |  | $ | 1,101 |  |  | $ | 1,013 |  |  | $ | 7,042 |  |  | $ | 5,509 |  |  | $ | 1,031 |  |  | $ | 881 |  |  | $ | 7,421 |
|  | Nine Months Ended September 30, 2022 |  | Nine Months Ended September 30, 2021
(in millions) |  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 6,088 |  |  | $ | 807 |  |  | $ | 577 |  |  | $ | 7,472 |  |  | $ | 4,926 |  |  | $ | 707 |  |  | $ | 461 |  |  | $ | 6,094 |
Complera/Eviplera |  | 56 |  |  | 76 |  |  | 10 |  |  | 142 |  |  | 73 |  |  | 104 |  |  | 12 |  |  | 189 |
Descovy |  | 1,152 |  |  | 92 |  |  | 91 |  |  | 1,335 |  |  | 994 |  |  | 128 |  |  | 105 |  |  | 1,227 |
Genvoya |  | 1,441 |  |  | 220 |  |  | 103 |  |  | 1,764 |  |  | 1,633 |  |  | 306 |  |  | 184 |  |  | 2,123 |
Odefsey |  | 763 |  |  | 278 |  |  | 36 |  |  | 1,077 |  |  | 773 |  |  | 336 |  |  | 39 |  |  | 1,148 |
Stribild |  | 68 |  |  | 23 |  |  | 7 |  |  | 98 |  |  | 94 |  |  | 33 |  |  | 12 |  |  | 139 |
Truvada |  | 77 |  |  | 12 |  |  | 13 |  |  | 102 |  |  | 268 |  |  | 18 |  |  | 24 |  |  | 310 |
Revenue share - Symtuza(1) |  | 251 |  |  | 126 |  |  | 10 |  |  | 388 |  |  | 261 |  |  | 125 |  |  | 8 |  |  | 394 |
Other HIV(2) |  | 11 |  |  | 20 |  |  | 15 |  |  | 45 |  |  | 110 |  |  | 19 |  |  | 24 |  |  | 153 |
Total HIV |  | 9,906 |  |  | 1,653 |  |  | 863 |  |  | 12,422 |  |  | 9,132 |  |  | 1,776 |  |  | 869 |  |  | 11,777 |
Veklury |  | 1,179 |  |  | 560 |  |  | 1,166 |  |  | 2,905 |  |  | 2,763 |  |  | 761 |  |  | 684 |  |  | 4,208 |
HCV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ledipasvir/Sofosbuvir(3) |  | 27 |  |  | 13 |  |  | 43 |  |  | 83 |  |  | 63 |  |  | 24 |  |  | 76 |  |  | 163 |
Sofosbuvir/Velpatasvir(4) |  | 629 |  |  | 288 |  |  | 244 |  |  | 1,161 |  |  | 649 |  |  | 234 |  |  | 272 |  |  | 1,155 |
Other HCV(5) |  | 88 |  |  | 31 |  |  | 7 |  |  | 127 |  |  | 97 |  |  | 64 |  |  | 9 |  |  | 170 |
Total HCV |  | 745 |  |  | 332 |  |  | 294 |  |  | 1,371 |  |  | 809 |  |  | 322 |  |  | 357 |  |  | 1,488 |
HBV/HDV
Vemlidy |  | 306 |  |  | 27 |  |  | 289 |  |  | 622 |  |  | 266 |  |  | 25 |  |  | 298 |  |  | 589 |
Viread |  | 4 |  |  | 17 |  |  | 48 |  |  | 69 |  |  | 8 |  |  | 22 |  |  | 55 |  |  | 85 |
Other HBV/HDV(6) |  | 1 |  |  | 41 |  |  | — |  |  | 42 |  |  | 1 |  |  | 29 |  |  | — |  |  | 30 |
Total HBV/HDV |  | 311 |  |  | 85 |  |  | 337 |  |  | 733 |  |  | 275 |  |  | 76 |  |  | 353 |  |  | 704 |
Cell therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 160 |  |  | 56 |  |  | 2 |  |  | 217 |  |  | 94 |  |  | 25 |  |  | — |  |  | 119 |
Yescarta |  | 528 |  |  | 253 |  |  | 42 |  |  | 823 |  |  | 300 |  |  | 188 |  |  | 25 |  |  | 513 |
Total cell therapy |  | 688 |  |  | 308 |  |  | 44 |  |  | 1,040 |  |  | 394 |  |  | 213 |  |  | 25 |  |  | 632 |
Trodelvy |  | 379 |  |  | 98 |  |  | 8 |  |  | 485 |  |  | 261 |  |  | 1 |  |  | — |  |  | 262 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 48 |  |  | 192 |  |  | 140 |  |  | 380 |  |  | 32 |  |  | 202 |  |  | 186 |  |  | 420 |
Letairis |  | 135 |  |  | — |  |  | — |  |  | 135 |  |  | 157 |  |  | — |  |  | — |  |  | 157 |
Other(7) |  | 91 |  |  | 52 |  |  | 35 |  |  | 178 |  |  | 109 |  |  | 68 |  |  | 23 |  |  | 200 |
Total other |  | 275 |  |  | 244 |  |  | 174 |  |  | 693 |  |  | 298 |  |  | 270 |  |  | 209 |  |  | 777 |
Total product sales |  | 13,482 |  |  | 3,281 |  |  | 2,887 |  |  | 19,650 |  |  | 13,932 |  |  | 3,419 |  |  | 2,497 |  |  | 19,848 |
Royalty, contract and other revenues |  | 140 |  |  | 98 |  |  | 4 |  |  | 242 |  |  | 70 |  |  | 140 |  |  | 3 |  |  | 213 |
Total revenues |  | $ | 13,622 |  |  | $ | 3,378 |  |  | $ | 2,891 |  |  | $ | 19,892 |  |  | $ | 14,002 |  |  | $ | 3,559 |  |  | $ | 2,500 |  |  | $ | 20,061 |
_______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). (2) Includes Atripla, Emtriva and Tybost. (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC. (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC. (5) Includes Vosevi and Sovaldi. (6) Includes Hepcludex and Hepsera. (7) Includes Cayston, Jyseleca, Ranexa and Zydelig. Revenues from Major Customers The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:
|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
(as a percentage of total revenues) |  | 2022 |  | 2021 |  | 2022 |  | 2021
AmerisourceBergen Corporation |  | 18 | % |  | 25 | % |  | 17 | % |  | 24 | %
Cardinal Health, Inc. |  | 25 | % |  | 22 | % |  | 25 | % |  | 21 | %
McKesson Corporation |  | 22 | % |  | 21 | % |  | 20 | % |  | 18 | %
Revenues Recognized from Performance Obligations Satisfied in Prior Periods The following table summarizes revenues recognized from performance obligations satisfied in prior periods:
|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
(in millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Revenue share with Janssen and royalties for licenses of intellectual property |  | $ | 192 |  |  | $ | 190 |  |  | $ | 573 |  |  | $ | 625 |
Changes in estimates |  | $ | 207 |  |  | $ | 188 |  |  | $ | 452 |  |  | $ | 661 |
Contract Balances Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $164 million and $174 million as of September 30, 2022 and December 31, 2021, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $85 million and $79 million as of September 30, 2022 and December 31, 2021, respectively.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI https://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration